Ozempic versus Wegovy: same medicine, very different purposes

Do Ozempic and Wegovy contain the same drug?

Yes, and that is precisely where the confusion starts. Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and influences blood-sugar regulation. The molecule is identical. What differs is the licensed indication, the approved dose range and, in practice, the clinical context in which a UK prescriber can use each one.

Ozempic is approved by the MHRA for adults with type 2 diabetes, to improve blood glucose control alongside diet and exercise. Its doses top out at 2mg weekly. Wegovy, by contrast, is approved specifically for weight management in adults with obesity (BMI 30 or above) or in those with a BMI from 27 with at least one weight-related condition. Its dose ladder runs from 0.25mg up to 2.4mg, and since April 2026 a 7.2mg single-dose pen has also received MHRA approval for adults with obesity. The NHS medicines information on semaglutide sets out both products clearly, and it is worth reading if you want the patient-level detail on how each is used.

So if someone tells you they are taking Ozempic for weight loss, they are either describing off-label use or they have confused the brand names, both happen regularly. A UK prescriber working within their licence cannot prescribe Ozempic for weight loss; Wegovy is the appropriate product for that conversation.

How do Ozempic and Wegovy compare on weight-loss results?

This question gets asked a lot, and it makes sense to be curious, even if the practical answer is that Ozempic is not the product to pursue for weight loss. For context: the landmark STEP 1 trial of semaglutide 2.4mg (Wegovy's dose) showed an average weight reduction of around 15% over 68 weeks in adults without diabetes, published in the New England Journal of Medicine. Ozempic at its highest dose (2mg) was not designed or trialled for weight loss as a primary outcome, and its dose ceiling is lower than Wegovy's maintenance dose, so comparing the two for that purpose is not clinically meaningful.

Wegovy at 7.2mg, in trials reported around the time of its MHRA approval, produced roughly 20.7% average weight loss over 72 weeks, narrowing the gap with the highest-dose tirzepatide data from SURMOUNT-1. If you want to understand how Ozempic and Wegovy stack up specifically for weight loss, our dedicated page works through the clinical evidence behind each. If you want to understand how semaglutide compares with liraglutide, another GLP-1 medicine used in weight management, our dedicated page sets out the clinical differences in detail. The short version: for weight management specifically, the licensed product is Wegovy, and the dose matters.

Numbers sourced from the MHRA product authorisations and NICE technology appraisal TA875.

If they are the same molecule, why can't a prescriber just use Ozempic for weight loss?

UK law and professional guidance are clear on this. A medicine's licensed indications reflect the evidence base submitted to the MHRA for that specific brand, dose and patient population. Wegovy was approved for weight management on the strength of the STEP trial programme; Ozempic was not submitted or approved for that purpose. Prescribing Ozempic off-label for weight loss would fall outside the licensed indication, carry different medicolegal considerations for the prescriber, and in any regulated online pharmacy setting would not be appropriate. The NHS England guidance on weight-management injections names the licensed products explicitly and makes the distinction plain.

There is also a supply-chain dimension. Ozempic has faced persistent shortages because of demand driven partly by off-label weight-loss use; the MHRA and NHS have repeatedly asked clinicians not to prescribe it for weight loss while those shortages affect diabetes patients who depend on it. That is a real-world harm that the licensing distinction is designed, in part, to prevent. If you are comparing these two products because you have seen Ozempic mentioned alongside weight loss online, this is the context missing from most of those conversations. You can read more about the key differences between Wegovy and Ozempic, including why that distinction matters in practice, on our dedicated comparison page, or read the extended version of this answer on how Wegovy and Ozempic differ for weight management.

What are the licensed weight-loss options in the UK, and how does a consultation work?

We understand the frustration of researching this, the brand names overlap, social media conflates them, and it can feel like everyone else knows something you don't. The actual picture is simpler. Two medicines currently hold UK MHRA licences for weight management in adults: Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). Tirzepatide is a dual GIP and GLP-1 receptor agonist, making it the only dual-agonist weight-loss medicine licensed here. If you are also weighing up the older injectable options, our page on how Saxenda compares with Wegovy walks through the key differences between those two licensed treatments.

At nume, our GPhC-registered prescribers review every consultation personally on the day it arrives. They look at your BMI, your health history, any medicines you take, and the clinical evidence for each option, then make a recommendation specific to you. There is no algorithm deciding. You can explore the Wegovy treatment overview for a fuller picture of how it works and what to expect, or browse our weight-loss treatment options to see both licensed injections side by side. If you are ready to talk through which licensed option fits your situation, speak to our prescribers through a free consultation, no referral, no waiting list.